SCHEMBL4755211

SCHEMBL4755211

COc1ccc(-n2ncc3c(Nc4cccc(NC(=O)c5cccc(C(F)(F)F)c5)c4)ncnc32)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.62
NPC1 O15118 6/20 0.62
RAB9A P51151 6/20 0.62
MEN1 O00255 5/20 0.62
KMT2A Q03164 5/20 0.62
KDM4E B2RXH2 5/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
ALDH1A1 P00352 3/20 0.62
GAA P10253 1/20 0.62
TP53 P04637 4/20 0.59
LMNA P02545 2/20 0.59
THRB P10828 1/20 0.59
KDR P35968 1/20 0.55
PIP4K2A P48426 2/20 0.53
PIK3CG P48736 1/20 0.53
PIP4K2C Q8TBX8 1/20 0.53
HPGD P15428 2/20 0.52
HSD17B10 Q99714 2/20 0.52
XBP1 P17861 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4917652 0.97 MAPT (0.62) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4917379 0.92 MAPT (0.62) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4187241 0.90 MAPK14 (0.57) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4919350 0.90 MAPT (0.54) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4697666 0.90 PIP4K2A (0.53) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4789574 0.89 MAPK14 (0.63) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4699408 0.88 MAPT (0.53) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4754428 0.84 RXFP1 (0.47) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4699789 0.82 LMNA (0.59) MAPTTP53LMNATHRBKDR
SCHEMBL4701650 0.81 MAPK14 (0.59) MAPTTP53LMNATHRBKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1963327-A1 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS Novartis AG (CH) 2008-09-03 EP claimed
WO-2007062805-A1 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS NOVARTIS AG (CH) 2007-06-07 WO claimed
US-20080275054-A1 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors HOLZER PHILIPP 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275054-A1 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors EPHB3, EPHB2, EPHB1 MAPT 2142/4885NPC1 4064/4885RAB9A 2817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.